The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05483-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Nemat Ali und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh, 11451, Saudi Arabia. Hauptthemen laut MEDLINE: Pentacyclic Triterpenes, Breast Neoplasms, Phenylthiohydantoin, Antineoplastic Agents. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Breast cancer is a leading cause of cancer and death in women. There is an urgent need to explore medicinal compounds that can enhance therapeutic effectiveness while minimizing toxicity. The present study utilized lupeol and enzalutamide combinations in luminal and triple-negative breast cancer cells to assess their efficacy on cell proliferation, apoptosis, and cell cycle progression. We performed a cell viability assay to investigate cytotoxicity using the spectrophotometric method. A combination index analysis was performed to determine synergistic dose drug combinations. Apoptosis and cell cycle analysis were performed using flow cytometry. The mRNA expression was analyzed by RT-PCR. Results indicate that lupeol + enzalutamide (Lup + Enz) significantly reduces cell viability in cancer cells compared to the treatment alone. The Caspase Glo assay revealed that Lup + Enz increased the activities of caspase 3/7 and 9 in the breast cancer cell line. Furthermore, Lup + Enz induces G1 phase arrest (≈75%) and promotes apoptosis (20%) in MCF-7 cells. mRNA expression suggests that Lup + Enz activates apoptotic mRNA expression (≈ 0.25 to threefold) in cancer cells. In conclusion, lupeol, in combination with enzalutamide, alters various hallmarks of breast cancer, like proliferation, apoptosis, and cell cycle arrest. Thus, lupeol may be a promising agent that enhances the outcomes of enzalutamide-based therapy. Further preclinical and clinical research is needed to validate the findings of this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh, 11451, Saudi Arabia.
- Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317, Saudi Arabia.
- Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
- Centre of Research Impact and Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
- Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317, Saudi Arabia.
- Department of Basic Medical Sciences, College of Medicine, Almaarefa University, Dariyah, 13713, Riyadh, Saudi Arabia.
Zitieren
APA
Ali, N., Alasiri, G., Babu, M. A., Singh, T. G., Alaseem, A. M., Quadri, M. S. A., Tyagi, Y., & Bansal, N. (2026). The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05483-7
Vancouver
Ali N, Alasiri G, Babu MA, Singh TG, Alaseem AM, Quadri MSA, et al. The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05483-7
BibTeX
@article{Ali2026,
author = {Ali, Nemat and Alasiri, Glowi and Babu, M Arockia and Singh, Thakur Gurjeet and Alaseem, Ali M and Quadri, Mohammed Sharique Ahmed and Tyagi, Yogita and Bansal, Nisha},
title = {The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05483-7}
}
EUVIMED